Adverse Drug Reaction News and Research

RSS
Researchers develop new tool to help avoid adverse reactions to drugs

Researchers develop new tool to help avoid adverse reactions to drugs

New poster presented at RCGP annual conference highlights dangers of hyperpolypharmacy

New poster presented at RCGP annual conference highlights dangers of hyperpolypharmacy

Study highlights need for additional systems to report adverse drug reactions in infants

Study highlights need for additional systems to report adverse drug reactions in infants

Clinical pharmacists in health care teams may improve quality, safety of patient care

Clinical pharmacists in health care teams may improve quality, safety of patient care

New computational method helps predict adverse drug reaction better than traditional computing methods

New computational method helps predict adverse drug reaction better than traditional computing methods

Promising new innovations in drug development, health monitoring may improve drug safety in the future

Promising new innovations in drug development, health monitoring may improve drug safety in the future

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Morphine after tonsillectomy may be life threatening for children

Morphine after tonsillectomy may be life threatening for children

Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

New clinical guidelines on diagnosis and management of idiosyncratic DILI

New clinical guidelines on diagnosis and management of idiosyncratic DILI

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

New uses for old drugs: an interview with Kate Hudson-Farmer, PhD MBA, Senior Consultant, Cambridge Consultants

New uses for old drugs: an interview with Kate Hudson-Farmer, PhD MBA, Senior Consultant, Cambridge Consultants

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials